Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies
Open Access
- 1 January 2020
- journal article
- review article
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 31 (Suppl 1) , 129-136
Abstract
The third decade of the 21st century marks the beginning of a new era in the treatment of rheumatoid arthritis (RA). Recently, after the introduction in clinical practice of different biologics in the first decade, three different oral synthetic targeted agents (JAK inhibitors) have been licensed for the treatment of RA, in patients who had failed or are intolerant to disease modifying anti-rheumatic drugs (DMARDs). Despite the significant progress that these agents bring to the care of RA patients, the risk of infections is still present and clear, given that their risk for serious infections is at least comparable with that of biologic DMARDs, whereas the incidence of herpes zoster is higher than that of bDMARDs. Here, we review the most recent data regarding the risk for serious and opportunistic infections in RA patients treated with biologics or JAK inhibitors, as well the up-to-date approach for managing and preventing such infections in RA patients.Keywords
This publication has 70 references indexed in Scilit:
- Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patientsMediterranean Journal of Rheumatology, 2018
- Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsAnnals of the Rheumatic Diseases, 2017
- Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease‐Modifying TherapyArthritis Care & Research, 2014
- Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International RecommendationsThe Journal of Rheumatology, 2014
- Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)Annals of the Rheumatic Diseases, 2014
- Herpes ZosterNew England Journal of Medicine, 2013
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of ExposureThe Journal of Rheumatology, 2013
- You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for tuberculosis) you get what you needAnnals of the Rheumatic Diseases, 2012
- Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsArthritis & Rheumatism, 2005
- Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infectionAnnals of the Rheumatic Diseases, 2004